Skip to content

Predictive Values of Presepsin Levels in ASciteS in Patients With Chronic Liver Failure

Predictive Values of Presepsin Levels in ASciteS in Patients With Chronic Liver Failure

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06224023
Acronym
PASS
Enrollment
30
Registered
2024-01-25
Start date
2024-08-01
Completion date
2024-12-31
Last updated
2024-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ascites Hepatic, Cirrhosis, Liver, Liver Failure

Brief summary

The investigators aim to study the predictive value of presepsin in ascites in newly admitted patients with chronic liver failure.

Detailed description

Presepsin is a plasmatic cleaved fragment of CD14. CD14 is a toll like receptor who has the role to identify certain lipopolysaccharides on the surface of bacteria (aerobes and anaerobes), thus promoting an inflammatory response. A study of 153 patients with liver cirrhosis published by a team of investigators from Iasi, Romania, has proven an useful role of plasma presepsin in early diagnosis of infections in patients in acute on chronic liver failure. In addition, plasma presepsin has been proposed as an independent predictor of mortality in patients with decompensated liver cirrhosis, without concomitant bacterial infections. Question to be answered by this study The investigators aim to evaluate the predictive role of ascites presepsin in patients with chronic liver failure. Hypothesis Presepsin levels in ascites may have a prognostic role in patients with ascites and chronic liver failure.

Interventions

DIAGNOSTIC_TESTDetermination of presepsin levels in ascites

A diagnostic paracentesis will be performed and presepsin level will be determined in ascites.

Sponsors

Carol Davila University of Medicine and Pharmacy
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patient with ascites and chronic liver failure * no contraindications and technical possibility to perform diagnostic paracentesis * age above 18 years old * informed consent

Exclusion criteria

* contraindications to paracentesis or technical impossibility to perform paracentesis * absence of informed consent

Design outcomes

Primary

MeasureTime frameDescription
Mortality at 6 months6 monthsNumber of who deceased during admission or during the 180 days after admission divided by the number of patients who were admitted. An analysis will be done to see if the presepsin levels are predictive for this event.

Secondary

MeasureTime frameDescription
Spontaneous bacterial peritonitis (SBP) rate6 monthsThe number of patients diagnosed with SBP during admission divided by the total number of patients. An analysis will be done to see if the presepsin levels are predictive for this event.
Hepatic encephalopathy rate6 monthsNumber of patients diagnosed with hepatic encephalopathy during admission divided by the total number of patients. An analysis will be done to see if the presepsin levels are predictive for this event.
Any infection rate6 monthsThe number of patients diagnosed with any infection during admission divided by the total number of patients. An analysis will be done to see if the presepsin levels are predictive for this event.

Countries

Romania

Contacts

Primary ContactMihai Ciocirlan
ciocirlanm@yahho.com0040722322625

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026